Back to Search
Start Over
Health-related quality of life and persistent symptoms in relation to (R-)CHOP14, (R-)CHOP21, and other therapies among patients with diffuse large B-cell lymphoma: results of the population-based PHAROS-registry
- Source :
- Annals of Hematology, 93(10), 1705-1715. Springer Verlag, Annals of Hematology, 93(10), 1705-1715. Springer-Verlag, Oerlemans, S, Issa, D E, van den Broek, E C, Nijziel, M R, Coebergh, J W W, Huijgens, P C, Mols, F & van de Poll-Franse, L 2014, ' Health-related quality of life and persistent symptoms in relation to (R-)CHOP14, (R-)CHOP21, and other therapies among patients with diffuse large B-cell lymphoma: results of the population-based PHAROS-registry ', Annals of Hematology, vol. 93, no. 10, pp. 1705-1715 . https://doi.org/10.1007/s00277-014-2099-8
- Publication Year :
- 2014
-
Abstract
- The increasing number of longer-living patients with diffuse large B-cell lymphoma (DLBCL) and serious side effects of treatment urged us to study the health-related quality of life (HRQoL) and persistent (treatment-related) symptoms in unselected patients after different treatment modalities and compare HRQoL of patients with a normative population. The population-based Eindhoven Cancer Registry was used to select all patients diagnosed with DLBCL from 2004 to 2010. The European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) was completed twice, with a 1-year interval. Detailed data on treatment were extracted from the Population-based HAematological Registry for Observational Studies. Two hundred fifty-six patients responded (84 %, T1). Compared to patients treated with rituximab combined with cyclophosphamide, doxorubicin, vincristine, and prednisone every 21 days ((R-)CHOP21), those who underwent (R-)CHOP14 more often reported tingling in the hands and feet (27 vs 42 %, p = 0.02) and fatigue (35 vs 46 %, p = 0.03) and reported a lower global health status/HRQoL. Mean HRQoL was statistically and clinically relevantly lower among DLBCL patients compared to a normative population (p Keywords: Quality of life, Non-Hodgkin lymphoma, Diffuse large B-cell lymphoma, Cancer survivors, Population-based, Treatment, PHAROS, PROFILES
- Subjects :
- Male
Gastrointestinal Diseases
Anxiety
Antibodies, Monoclonal, Murine-Derived
Quality of life
Prednisone
Surveys and Questionnaires
Antineoplastic Combined Chemotherapy Protocols
Registries
Survivors
Fatigue
Netherlands
Aged, 80 and over
education.field_of_study
Hematology
General Medicine
Middle Aged
humanities
Patient Satisfaction
Vincristine
Rituximab
Female
Lymphoma, Large B-Cell, Diffuse
Symptom Assessment
medicine.drug
Adult
medicine.medical_specialty
Population
Patient satisfaction
SDG 3 - Good Health and Well-being
Internal medicine
medicine
Humans
Paresthesia
education
Cyclophosphamide
Aged
business.industry
medicine.disease
Surgery
Cancer registry
Doxorubicin
Quality of Life
Neuralgia
business
Diffuse large B-cell lymphoma
Follow-Up Studies
Subjects
Details
- ISSN :
- 09395555
- Volume :
- 93
- Issue :
- 10
- Database :
- OpenAIRE
- Journal :
- Annals of Hematology
- Accession number :
- edsair.doi.dedup.....5702fdca9be16e27df5e115c8c503766